BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock News

This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE...

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

-  Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data  - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) --...

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

The reason for the stock's rapid ascent is a mystery.

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”)...

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a...

MarketBeat Week in Review – 10/14 - 10/18

Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.

What's Going On With Bright Minds Biosciences Stock Friday?

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN...

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models ...

Bright Minds Biosciences Stock Surges Almost 1,500%

Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Bright Minds Biosciences Inc. (NASDAQ: DRUG) is excited to announce its participation in the upcoming scientific conferences...

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Bright Minds Biosciences will host the Key Opinion Leader event with leading experts in epilepsy research and treatment on September 25...

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

/PRNewswire/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and...

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

/CNW/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric...

DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024

Bright Minds Biosciences just reported results for the third quarter of 2024.

DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bright Minds Biosciences (NASDAQ:DRUG) just reported results for the third quar...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!

DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024

Bright Minds Biosciences just reported results for the second quarter of 2024.